AstraZeneca PLC (AZN)
162.13
-0.57
(-0.35%)
USD |
NYSE |
Aug 31, 16:00
162.51
+0.38
(+0.23%)
Pre-Market: 08:57
AstraZeneca Net Income (TTM) : 10.40B for March 31, 2026
Net Income (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 10.40B |
| December 31, 2025 | 10.24B |
| September 30, 2025 | 9.405B |
| June 30, 2025 | 8.318B |
| March 31, 2025 | 7.768B |
| December 31, 2024 | 7.027B |
| September 30, 2024 | 6.50B |
| June 30, 2024 | 6.445B |
| March 31, 2024 | 6.337B |
| December 31, 2023 | 5.961B |
| September 30, 2023 | 5.904B |
| June 30, 2023 | 6.168B |
| March 31, 2023 | 4.708B |
| December 31, 2022 | 3.292B |
| September 30, 2022 | 2.044B |
| June 30, 2022 | -1.249B |
| March 31, 2022 | -1.059B |
| December 31, 2021 | 115.00M |
| September 30, 2021 | 1.466B |
| June 30, 2021 | 3.768B |
| March 31, 2021 | 3.956B |
| December 31, 2020 | 3.144B |
| September 30, 2020 | 2.416B |
| June 30, 2020 | 2.045B |
| March 31, 2020 | 1.414B |
| Date | Value |
|---|---|
| December 31, 2019 | 1.227B |
| September 30, 2019 | 1.959B |
| June 30, 2019 | 2.085B |
| March 31, 2019 | 2.297B |
| December 31, 2018 | 2.052B |
| September 30, 2018 | 2.304B |
| June 30, 2018 | 2.547B |
| March 31, 2018 | 2.674B |
| December 31, 2017 | 2.868B |
| September 30, 2017 | 3.424B |
| June 30, 2017 | 3.770B |
| March 31, 2017 | 3.293B |
| December 31, 2016 | 3.400B |
| September 30, 2016 | 2.391B |
| June 30, 2016 | 2.166B |
| March 31, 2016 | 2.893B |
| December 31, 2015 | 2.826B |
| September 30, 2015 | 1.699B |
| June 30, 2015 | 1.180B |
| March 31, 2015 | 1.285B |
| December 31, 2014 | 1.241B |
| September 30, 2014 | 1.025B |
| June 30, 2014 | 2.009B |
| March 31, 2014 | 2.021B |
| December 31, 2013 | 2.506B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| GSK Plc | 7.078B |
| Johnson & Johnson | 21.04B |
| Eli Lilly & Co. | 26.71B |
| Merck & Co., Inc. | 3.169B |
| Novo Nordisk A/S | 18.19B |